Alercell Lena Q51 Leukemia Diagnostic Test (RUO)
Alercell, a Bozeman, Montana-based molecular diagnostics company, has launched the Lena Q51 leukemia diagnostics test for research use only. The assay is designed to detect up to 51 gene mutations associated with leukemia in order to improve patient outcomes and help physicians select appropriate therapeutics for leukemia patients. Test results are available in under three hours using a standard qPCR machine and standard PCR and DNA purification technology, the company said. Alercell is also currently completing clinical trials and regulatory submissions to support US Food and Drug Administration approval.